




Instance: composition-en-f502911808bc1b6ee8b26c1badf235f8
InstanceOf: CompositionUvEpi
Title: "Composition for slenyto Package Leaflet"
Description:  "Composition for slenyto Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpf502911808bc1b6ee8b26c1badf235f8)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - slenyto"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Slenyto is and what it is used for </li>
<li>What you need to know before you or your child takes Slenyto </li>
<li>How to take Slenyto </li>
<li>Possible side effects </li>
<li>How to store Slenyto </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What slenyto is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What slenyto is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Slenyto is 
Slenyto is a medicine that contains the active ingredient, melatonin. Melatonin is a hormone produced 
naturally by the body. </p>
<p>What it is used for 
Slenyto is for use in children and adolescents (2 to 18 years old) with autism spectrum disorder 
(ASD) and/or Smith-Magenis syndrome, a neurogenetic disease (inherited condition affecting the 
nerves and brain). </p>
<p>Slenyto shortens the time it takes to fall asleep and lengthens the duration of sleep. 
It is for the treatment of insomnia (sleeplessness) when a healthy sleeping routine (such as a regular 
bedtime and soothing sleeping environment) has not worked well enough.  The medicine can help you 
or your child fall asleep and may help you or your child sleep for longer during the night. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take slenyto"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take slenyto"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>DO NOT take Slenyto if you or your child 
- is allergic to melatonin or any of the other ingredients of this medicine (listed in section 6). </p>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before taking Slenyto if you or your child:</p>
<ul>
<li>has liver or kidney problems. You should speak to your doctor before taking/giving Slenyto as 
its use is not recommended in such cases. </li>
<li>suffers from an autoimmune disease (where the body s own immune (defence) system attacks 
parts of the body). You should speak to your doctor before taking/giving Slenyto as its use is 
not recommended in such cases. </li>
<li>feels drowsy (see section below on  Driving and using machines ). </li>
</ul>
<p>Children under 2 years old<br />
Do not give this medicine to children below the age of 2 years as it has not been tested and its effects 
are unknown. </p>
<p>Other medicines and Slenyto </p>
<p>Tell your doctor or pharmacist if you or your child is taking, has recently taken or might take any other 
medicines.   </p>
<p>In particular, taking Slenyto with the following medicines can increase the risk of side effects, or it can 
affect the way that Slenyto or the other medicine works: </p>
<ul>
<li>fluvoxamine (used for the treatment of depression and obsessive compulsive disorder) </li>
<li>methoxypsoralens (used in the treatment of skin disorders e.g. psoriasis) </li>
<li>cimetidine (used in the treatment of stomach problems such as ulcers) </li>
<li>quinolones (for example ciprofloxacin and norfloxacin) and rifampicin (used in the treatment 
of bacterial infections) </li>
<li>oestrogens (used in contraceptives or hormone replacement therapy)  </li>
<li>carbamazepine (used in the treatment of epilepsy) </li>
<li>non-steroidal anti-inflammatory medicines such as aspirin and ibuprofen (used for treating 
pain and inflammation). These medicines should be avoided, especially in the evening. </li>
<li>beta-blockers (used to control blood pressure). These medicines should be taken in the 
morning. </li>
<li>benzodiazepines and non-benzodiazepine hypnotics such as zaleplon, zolpidem and zopiclone 
(used to induce sleep) </li>
<li>thioridazine (used for the treatment of schizophrenia) </li>
<li>imipramine (used for the treatment of depression) </li>
</ul>
<p>Smoking 
Smoking can increase the breakdown of melatonin by the liver, which may make this medicine less 
effective. Please tell your doctor if you or your child starts or stops smoking during treatment. </p>
<p>Slenyto with alcohol 
Do not drink alcohol before, during or after taking Slenyto, because alcohol weakens the effect of the 
medicine. </p>
<p>Pregnancy and breast-feeding 
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask 
your doctor for advice before taking this medicine. </p>
<p>Tell your doctor or pharmacist before using Slenyto if you or your daughter: 
* is pregnant or might be pregnant.  As a precautionary measure, it is preferable to avoid the use 
of melatonin during pregnancy. 
* is breast-feeding or planning to breast-feed. It is possible that melatonin is passed into human 
breast milk, therefore your doctor will decide whether you or your daughter should breastfeed 
whilst taking melatonin. </p>
<p>Driving and using machines 
Slenyto may cause drowsiness.  After taking this medicine, you or your child should not drive a 
vehicle, ride a bicycle, or use machinery until completely recovered. </p>
<p>If you or your child suffers from continued drowsiness, you should consult your doctor. </p>
<p>Slenyto contains lactose<br />
Slenyto contains lactose monohydrate.  If you or your child has been told by your doctor that you have 
an intolerance to some sugars, contact your doctor before taking this medicinal product.  </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take slenyto"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take slenyto"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if 
you are not sure. </p>
<p>How much 
Slenyto is available in two strengths: 1 mg and 5 mg.  The recommended starting dose is 2 mg (two 
1-mg tablets) once daily. If there is no improvement in your/your child s symptoms, your doctor may 
increase the dose of Slenyto to find the most suitable dose for you/your child. The maximum daily 
dose that you/your child will receive is 10 mg (two 5-mg tablets). </p>
<p>When<br />
Slenyto should be taken in the evening, 30 to 60 minutes before bedtime. The tablets should be taken 
after the evening meal, i.e. on a full stomach. </p>
<p>How to take Slenyto 
Slenyto is for oral use. The tablets should be swallowed whole and NOT broken, crushed or 
chewed.  Crushing and chewing damages the special properties of the tablet and means that they will 
not work properly. </p>
<p>The whole tablets can be put into food like yoghurt, orange juice or ice-cream to help with 
swallowing. If the tablets are mixed with these foods, they should be given immediately and not left or 
stored, as this may affect the way the tablets work.  If the tablets are mixed with any other type of 
food, the tablets may not work properly. </p>
<p>How long 
You or your child should be monitored by your doctor at regular intervals (recommended every 
6 months) to check that Slenyto is still the right treatment for you/them.   </p>
<p>If you or your child takes more Slenyto than you/they should 
If you/your child has accidentally taken too much medicine, contact the doctor or pharmacist as soon 
as possible. </p>
<p>Taking more than the recommended daily dose may make you/your child feel drowsy. </p>
<p>If you or your child forgets to take Slenyto 
If you or your child forgets to take a tablet, it could be taken before going to sleep that night, but after 
this time, no other tablet should be taken before the next evening. 
Do not take a double dose to make up for a forgotten dose. </p>
<p>If you or your child stops taking Slenyto 
You should talk to your doctor before you/your child stops taking Slenyto. It is important to continue 
taking this medicine to treat the condition. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Unexpected changes in behaviour, such as aggression, may occur commonly (affecting between 1 in 
100 to 1 in 10 people). If this change in behaviour occurs, you must tell your doctor. The doctor 
may want you/your child to stop taking this medicine. </p>
<p>If any of the following side effects get serious or are troublesome, contact your doctor or seek medical 
advice: </p>
<p>Common: may affect between 1 in 100 to 1 in 10 people </p>
<ul>
<li>Changes in mood </li>
<li>Aggression </li>
<li>Irritability </li>
<li>Drowsiness </li>
<li>Headache </li>
<li>Sudden onset of sleep </li>
<li>Swelling and inflammation of the sinuses associated with pain and blocked nose (sinusitis) </li>
<li>Tiredness </li>
<li>Hangover feeling </li>
</ul>
<p>Uncommon: may affect between 1 in 1000 to 1 in 100 people </p>
<ul>
<li>Depression </li>
<li>Nightmares </li>
<li>Agitation </li>
<li>Stomach ache </li>
</ul>
<p>Frequency not known (reported with another pharmaceutical form and strength) </p>
<ul>
<li>Fits (epilepsy) </li>
<li>Visual impairment </li>
<li>Breathlessness/shortness of breath (dyspnoea) </li>
<li>Nose bleeds (epistaxis) </li>
<li>Constipation </li>
<li>Decreased appetite </li>
<li>Swelling of the face </li>
<li>Skin lesion </li>
<li>Feeling abnormal </li>
<li>Abnormal behaviour </li>
<li>Low levels of white blood cells (neutropenia) </li>
</ul>
<p>Reporting of side effects 
If you or your child gets any side effects, talk to your doctor or pharmacist.  This includes any possible 
side effects not listed in this leaflet.  You can also report side effects directly via the national reporting 
system listed in Appendix V.  By reporting side effects you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store slenyto"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store slenyto"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP.  The 
expiry date refers to the last day of that month. </p>
<p>Do not store above 30 C.   </p>
<p>Do not throw away any medicines via wastewater or household waste.  Ask your pharmacist how to 
throw away medicines you no longer use.  These measures will help to protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Slenyto contains </p>
<p>1 mg strength </p>
<ul>
<li>The active substance is melatonin.  Each tablet contains 1 mg melatonin. </li>
<li>The other ingredients are ammonio methacrylate copolymer type B, calcium hydrogen 
phosphate dihydrate, lactose monohydrate, silica (colloidal anhydrous), talc, magnesium 
stearate, carmellose sodium (E466), maltodextrin, glucose monohydrate, lecithin (E322), 
titanium dioxide (E171), iron oxide red (E172) and iron oxide yellow (E172). </li>
</ul>
<p>5 mg strength </p>
<ul>
<li>The active substance is melatonin.  Each tablet contains 5 mg melatonin. </li>
<li>The other ingredients are ammonio methacrylate copolymer type A, calcium hydrogen 
phosphate dihydrate, lactose monohydrate, silica (colloidal anhydrous), magnesium stearate, 
carmellose sodium (E466), maltodextrin, glucose monohydrate, lecithin (E322), titanium 
dioxide (E171) and iron oxide yellow (E172). </li>
</ul>
<p>What Slenyto looks like and contents of the pack </p>
<p>1 mg strength </p>
<p>Slenyto 1 mg prolonged-release tablets are pink, film coated, round, biconvex, 3 mm diameter tablets. </p>
<p>Available in blister packs of 30 / 60 tablets. </p>
<p>5 mg strength </p>
<p>Slenyto 5 mg prolonged-release tablets are yellow, film coated, round, biconvex, 3 mm diameter 
tablets. </p>
<p>Available in blister packs of 30 tablets. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder </p>
<p>RAD Neurim Pharmaceuticals EEC SARL 
4 rue de Marivaux 
75002 Paris 
France<br />
e-mail: regulatory@neurim.com </p>
<p>Manufacturer </p>
<p>Iberfar Ind stria Farmac utica, S.A. 
Estrada Consiglieri Pedroso 123,<br />
Queluz De Baixo 
Barcarena 
2734-Portugal </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
RAD Neurim Pharmaceuticals EEC SARL 
T l/Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Lietuva 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>RAD Neurim Pharmaceuticals EEC SARL 
Te .: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Luxembourg/Luxemburg 
RAD Neurim Pharmaceuticals EEC SARL 
T l/Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>esk  republika 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com 
Magyarorsz g 
RAD Neurim Pharmaceuticals EEC SARL 
Tel.: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Danmark 
Takeda Pharma A/S 
e-mail: medinfoEMEA@takeda.com </p>
<p>Malta 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Deutschland 
INFECTOPHARM Arzneimittel und Consilium 
GmbH 
Tel: +49 6252 957e-mail: kontakt@infectopharm.com </p>
<p>Nederland 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Eesti 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Norge 
Takeda AS 
e-mail: medinfoEMEA@takeda.com </p>
<p>INNOVIS PHARMA A.E.B.E. 
 : +30 216 200 5e-mail: info@innovispharma.gr </p>
<p>sterreich 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Espa a 
EXELTIS HEALTHCARE, S.L. 
Tel: +34 91 7711e-mail: RegistrosExeltisSpain@exeltis.com </p>
<p>Polska 
RAD Neurim Pharmaceuticals EEC SARL<br />
Tel.: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>France 
BIOCODEX 
T l: +33 (0)1 41 24 30 e-mail: medinfo@biocodex.com </p>
<p>Portugal 
Laborat rios Azevedos   Ind stria Farmac utica, 
S.A. 
Tel: +351 214 725 e-mail: mail@azevedos-sa.pt </p>
<p>Hrvatska 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Rom nia 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Ireland 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Slovenija 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>sland 
Williams &amp; Halls ehf.<br />
S mi: +354 527 0Netfang: info@wh.is </p>
<p>Slovensk  republika 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Italia 
Fidia Farmaceutici S.p.A. 
Tel: +39 049 8232e-mail: info@fidiapharma.it </p>
<p>Suomi/Finland 
RAD Neurim Pharmaceuticals EEC SARL 
Puh/Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>RAD Neurim Pharmaceuticals EEC SARL 
 : +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Sverige 
Takeda Pharma AB 
e-mail: medinfoEMEA@takeda.com </p>
<p>Latvija 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com 
United Kingdom (Northern Ireland) 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>This leaflet was last revised in { month/YYYY}. </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-f502911808bc1b6ee8b26c1badf235f8
InstanceOf: CompositionUvEpi
Title: "Composition for slenyto Package Leaflet"
Description:  "Composition for slenyto Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpf502911808bc1b6ee8b26c1badf235f8)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - slenyto"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du eller dit barn begynder at tage Slenyto 
3. Sådan skal du tage Slenyto 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What slenyto is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What slenyto is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Hvad er Slenyto? 
Slenyto er et lægemiddel, der indeholder det aktive stof melatonin. Melatonin er et hormon, der 
naturligt dannes af kroppen. </p>
<p>Hvad anvendes det til? 
Slenyto er til anvendelse hos børn og unge (2 til 18 år) med autismespektrumforstyrrelse (ASD) 
og/eller Smith-Magenis-syndrom, der er en neurogenetisk sygdom (dvs. en arvelig sygdom, som 
påvirker nerverne og hjernen). </p>
<p>Slenyto forkorter den tid, det tager at falde i søvn, og forlænger søvnen. 
Det er beregnet til at behandle søvnløshed, når sunde soverutiner (såsom regelmæssige sengetider 
og et beroligende sovemiljø) ikke har virket tilstrækkeligt. Lægemidlet kan hjælpe dig eller dit barn til 
at falde i søvn og kan hjælpe dig eller dit barn til at sove længere om natten. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take slenyto"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take slenyto"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag IKKE Slenyto hvis du eller dit barn 
- er allergisk over for melatonin eller et af de øvrige indholdsstoffer i dette lægemiddel (angivet i 
afsnit 6). </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apoteket før indtagelse af Slenyto, hvis du eller dit barn:</p>
<ul>
<li>har lever- eller nyreproblemer. Tal med lægen før indtagelse af Slenyto, da det frarådes at tage 
det i sådanne tilfælde. </li>
<li>har en autoimmun sygdom (hvor kroppens eget forsvarssystem (immunforsvaret) angriber dele 
af kroppen). Tal med lægen før indtagelse af Slenyto, da det frarådes at tage det i sådanne 
tilfælde. </li>
<li>føler dig/sig døsig (se afsnittet under "Trafik- og arbejdssikkerhed"). </li>
</ul>
<p>Børn under 2 år<br />
Giv ikke dette lægemiddel til børn under 2 år, da det ikke er testet, og dets virkninger er ukendte. </p>
<p>Brug af anden medicin sammen med Slenyto </p>
<p>Fortæl altid lægen eller apotekspersonalet, hvis du eller dit barn bruger anden medicin, for nylig har 
brugt anden medicin eller planlægger at bruge anden medicin.  </p>
<p>Navnlig medfører det øget risiko for bivirkninger at tage Slenyto sammen med følgende lægemidler, 
eller det kan påvirke den måde, som Slenyto eller det andet lægemiddel virker på: </p>
<ul>
<li>
<p>fluvoxamin (anvendes til behandling af depression og tvangstanker (obsessiv-kompulsiv 
lidelse) </p>
</li>
<li>
<p>methoxpsoralen (anvendes til behandling af hudsygdomme, f.eks. psoriasis) </p>
</li>
<li>
<p>cimetidin (anvendes til behandling af maveproblemer såsom sår) </p>
</li>
<li>
<p>quinoloner (f.eks. ciprofloxacin og norfloxacin) og rifampicin (anvendes til behandling af 
bakterielle infektioner) </p>
</li>
<li>
<p>østrogener (anvendes som svangerskabsforebyggende midler eller som 
hormonerstatningsbehandling)  </p>
</li>
<li>
<p>carbamazepin (anvendes til behandling af epilepsi) </p>
</li>
<li>
<p>nonsteroide antiinflammatoriske lægemidler såsom acetylsalicylsyre og ibuprofen (anvendes 
til behandling af smerter og inflammation) Disse lægemidler bør undgås, navnlig om aftenen. </p>
</li>
<li>
<p>betablokkere (anvendes til kontrol af blodtrykket). Disse lægemidler bør tages om morgenen. </p>
</li>
<li>
<p>sovemidler (benzodiazepiner og ikke-benzodiazepiner såsom zaleplon, zolpidem og zopiclon) </p>
</li>
<li>
<p>thioridazin (anvendes til behandling af skizofreni) </p>
</li>
<li>
<p>imipramin (anvendes til behandling af depression) </p>
</li>
</ul>
<p>Rygning 
Rygning kan øge nedbrydningen af melatonin i leveren, hvilket kan gøre dette lægemiddel mindre 
effektivt. Fortæl det til lægen, hvis du eller dit barn begynder at ryge eller holder op med at ryge under 
behandlingen. </p>
<p>Alkoholindtagelse og Slenyto 
Indtag ikke alkohol før, under eller efter indtagelse af Slenyto, da alkohol nedsætter lægemidlets 
virkning. </p>
<p>Graviditet og amning 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge til råds, før du bruger dette lægemiddel. </p>
<p>Kontakt lægen eller apoteket før indtagelse af Slenyto, hvis du eller din datter: </p>
<ul>
<li>
<p>er gravid eller kan tænkes at være gravid. Som forsigtighedsregel må det foretrækkes at undgå 
anvendelse af melatonin under graviditet. </p>
</li>
<li>
<p>ammer eller planlægger at amme. melatonin går muligvis over i modermælk; lægen vil derfor 
afgøre, om du/din datter bør amme under behandlingen med melatonin. </p>
</li>
</ul>
<p>Trafik- og arbejdssikkerhed 
Slenyto kan forårsage døsighed. Efter at have taget dette lægemiddel bør du eller dit barn ikke føre 
motorkøretøj, cykle eller betjene maskiner, før virkningen helt har fortaget sig.  </p>
<p>Hvis du eller dit barn er vedvarende døsig, bør du kontakte lægen. </p>
<p>Slenyto indeholder lactose<br />
Slenyto indeholder lactosemonohydrat. Hvis lægen har fortalt dig, at du eller dit barn ikke tåler visse 
sukkerarter, skal du kontakte lægen, før du eller dit barn tager dette lægemiddel.  </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take slenyto"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take slenyto"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller på apoteket. </p>
<p>Hvor meget 
Slenyto fås i to styrker: 1 mg og 5 mg. Den anbefalede startdosis er 2 mg (to 1-mg tabletter) 1 gang 
dagligt. Hvis der ikke er bedring i dine eller dit barns symptomer, vil lægen muligvis sætte dosis af 
Slenyto op for at finde den bedst egnede dosis til dig/dit barn. Den maksimale daglige dosis, som 
du/dit barn vil få, er 10 mg (to 5 mg-tabletter). </p>
<p>Hvornår<br />
Slenyto bør tages om aftenen, 30-60 minutter før sengetid. Tabletterne bør tages efter aftensmaden, 
dvs. på fuld mave. </p>
<p>Sådan skal du tage Slenyto 
Slenyto er til oral brug. Tabletterne synkes hele og må IKKE deles, knuses eller tygges. Hvis 
tabletten knuses eller tygges, vil det beskadige dens særlige egenskaber, så den ikke virker korrekt. </p>
<p>De hele tabletter kan kommes i fødevarer såsom yoghurt, appelsinjuice eller is for at gøre det lettere 
at synke dem. Når tabletterne er blandet i sådanne fødevarer, skal de gives straks og ikke henstå eller 
opbevares, da dette kan påvirke den måde, tabletterne virker på. Hvis tabletterne blandes med andre 
typer fødevarer, vil tabletterne muligvis ikke virke korrekt. </p>
<p>Hvor længe 
Du eller dit barn bør kontrolleres af lægen med jævne mellemrum (hver 6. måned anbefales) for at 
sikre, at Slenyto stadig er den rigtige behandling for dig/barnet.  </p>
<p>Hvis du eller dit barn får for meget Slenyto 
Hvis du eller barnet ved fejl har taget for meget lægemiddel, skal du kontakte lægen eller apoteket 
snarest muligt. </p>
<p>Ved at tage mere end den anbefalede daglige dosis kan du/dit barn blive døsig. </p>
<p>Hvis du eller dit barn har glemt at tage Slenyto 
Hvis du eller dit barn glemmer at tage en tablet, kan den tages før sengetid samme aften, men efter 
dette tidspunkt bør der ikke tages endnu en tablet før næste aften. 
Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. </p>
<p>Hvis du eller dit barn holder op med at tage Slenyto 
Tal med lægen, før du eller dit barn holder op med at tage Slenyto. Det er vigtigt at fortsætte med at 
tage dette lægemiddel for at behandle sygdommen. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Uventet ændret adfærd, såsom aggression, kan forekomme almindeligt (hos mellem 1 ud af 100 og 1 
ud af 10 personer). Indtræder der en sådan ændring i adfærd, skal du sige det til lægen. Lægen 
kan muligvis afgøre, at du eller dit barn bør holde op med at tage dette lægemiddel. </p>
<p>Bliver nogen af følgende bivirkninger alvorlige eller generende, skal du kontakte lægen eller søge 
medicinsk rådgivning: </p>
<p>Almindelig: kan optræde hos mellem 1 ud af 100 til 1 ud af 10 personer </p>
<ul>
<li>
<p>Humørændringer </p>
</li>
<li>
<p>Aggression </p>
</li>
<li>
<p>Irritabilitet </p>
</li>
<li>
<p>Døsighed </p>
</li>
<li>
<p>Hovedpine </p>
</li>
<li>
<p>Pludselig falden i søvn </p>
</li>
<li>
<p>Hævelse og betændelse i bihulerne sammen med smerter og stoppet næse (bihulebetændelse) </p>
</li>
<li>
<p>Træthed </p>
</li>
<li>
<p>Tømmermænd </p>
</li>
</ul>
<p>Ikke almindelig: kan optræde hos mellem 1 ud af 1000 til 1 ud af 100 personer </p>
<ul>
<li>
<p>Depression </p>
</li>
<li>
<p>Mareridt </p>
</li>
<li>
<p>Rastløs uro </p>
</li>
<li>
<p>Mavesmerter </p>
</li>
</ul>
<p>Hyppighed kendes ikke (rapporteret med anden form for lægemiddel og styrke) </p>
<ul>
<li>
<p>Anfald (epilepsi) </p>
</li>
<li>
<p>Synsnedsættelse </p>
</li>
<li>
<p>Åndenød (dyspnø) </p>
</li>
<li>
<p>Næseblod </p>
</li>
<li>
<p>Forstoppelse </p>
</li>
<li>
<p>Nedsat appetit </p>
</li>
<li>
<p>Hævet ansigt </p>
</li>
<li>
<p>Hudforandringer </p>
</li>
<li>
<p>Følelse af at være unormal </p>
</li>
<li>
<p>Abnorm adfærd </p>
</li>
<li>
<p>Lavt antal hvide blodlegemer (neutropeni) </p>
</li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du eller dit barn oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store slenyto"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store slenyto"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på pakningen efter EXP. Udløbsdatoen er den 
sidste dag i den nævnte måned. </p>
<p>Må ikke opbevares ved temperaturer over 30 °C.  </p>
<p>Af hensyn til miljøet må du ikke smide medicinrester i afløbet, toilettet eller skraldespanden. Spørg 
apotekspersonalet, hvordan du skal bortskaffe medicinrester. Dette vil medvirke til at skåne miljøet. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Slenyto indeholder: </p>
<p>Styrke 1 mg </p>
<ul>
<li>Aktivt stof: melatonin. Hver tablet indeholder 1 mg melatonin. </li>
<li>De øvrige indholdsstoffer er ammoniummethacrylat-copolymer type B, 
calciumhydrogenphosphatdihydrat, lactosemonohydrat, silica (kolloid vandfri), talkum, 
magnesiumstearat, carmellosenatrium (E466), maltodextrin, glucosemonohydrat, lecithin 
(E322), titandioxid (E171), jernoxid, rød (E172) og jernoxid, gul (E172). </li>
</ul>
<p>Styrke 5 mg </p>
<ul>
<li>Aktivt stof: melatonin. Hver tablet indeholder 5 mg melatonin. </li>
<li>De øvrige indholdsstoffer er ammoniummethacrylat-copolymer type A, 
calciumhydrogenphosphatdihydrat, lactosemonohydrat, silica (kolloid vandfri), 
magnesiumstearat, carmellosenatrium (E466), maltodextrin, glucosemonohydrat, lecithin 
(E322), titandioxid (E171), og jernoxid, gul (E172). </li>
</ul>
<p>Udseende og pakningsstørrelser </p>
<p>Styrke 1 mg </p>
<p>Slenyto depottabletter, 1 mg, er lyserøde, filmovertrukne, runde, bikonvekse tabletter med diameter 
3 mm. </p>
<p>De fås i blisterpakning med 30/60 tabletter. </p>
<p>Styrke 5 mg </p>
<p>Slenyto depottabletter, 5 mg, er gule, filmovertrukne, runde, bikonvekse tabletter med diameter 3 mm. </p>
<p>De fås i blisterpakning med 30 tabletter. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen </p>
<p>RAD Neurim Pharmaceuticals EEC SARL 
4 rue de Marivaux 
75002 Paris 
Frankrig<br />
e-mail: regulatory@neurim.com </p>
<p>Fremstiller </p>
<p>Iberfar Indústria Farmacêutica S.A., 
Estrada Consiglieri Pedroso 123,<br />
Queluz De Baixo 
Barcarena 
2734 -Portugal </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
RAD Neurim Pharmaceuticals EEC SARL 
Tél/Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Lietuva 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>България 
RAD Neurim Pharmaceuticals EEC SARL 
Teл.: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Luxembourg/Luxemburg 
RAD Neurim Pharmaceuticals EEC SARL 
Tél/Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Česká republika 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com 
Magyarország 
RAD Neurim Pharmaceuticals EEC SARL 
Tel.: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Danmark 
Takeda Pharma A/S 
e-mail: medinfoEMEA@takeda.com </p>
<p>Malta 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Deutschland 
INFECTOPHARM Arzneimittel und Consilium 
GmbH 
Tel: +49 6252 957e-mail: kontakt@infectopharm.com </p>
<p>Nederland 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Eesti 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Norge 
Takeda AS 
e-mail: medinfoEMEA@takeda.com 
Ελλάδα 
INNOVIS PHARMA A.E.B.E. 
Τηλ: +30 216 200 5e-mail: info@innovispharma.gr </p>
<p>Österreich 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>España 
EXELTIS HEALTHCARE, S.L. 
Tel: +34 91 7711e-mail: RegistrosExeltisSpain@exeltis.com </p>
<p>Polska 
RAD Neurim Pharmaceuticals EEC SARL<br />
Tel.: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>France 
BIOCODEX 
Tél: +33 (0)1 41 24 30 e-mail: medinfo@biocodex.com </p>
<p>Portugal 
Laboratórios Azevedos - Indústria Farmacêutica, 
S.A. 
Tel: +351 214 725 e-mail: mail@azevedos-sa.pt </p>
<p>Hrvatska 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>România 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Ireland 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Slovenija 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Ísland 
Williams &amp; Halls ehf. 
Sími: +354 527 0Netfang: info@wh.is </p>
<p>Slovenská republika 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Italia 
Fidia Farmaceutici S.p.A. 
Tel: +39 049 8232e-mail: info@fidiapharma.it </p>
<p>Suomi/Finland 
RAD Neurim Pharmaceuticals EEC SARL 
Puh/Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Κύπρος 
RAD Neurim Pharmaceuticals EEC SARL 
Τηλ: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Sverige 
Takeda Pharma AB 
e-mail: medinfoEMEA@takeda.com </p>
<p>Latvija 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com 
United Kingdom (Northern Ireland) 
RAD Neurim Pharmaceuticals EEC SARL 
Tel: +33 185149776 (FR) 
e-mail: neurim@neurim.com </p>
<p>Denne indlægsseddel blev senest ændret {måned ÅÅÅÅ}. </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-f502911808bc1b6ee8b26c1badf235f8
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for slenyto Package Leaflet for language en"
Description: "ePI document Bundle for slenyto Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-f502911808bc1b6ee8b26c1badf235f8"
* entry[0].resource = composition-en-f502911808bc1b6ee8b26c1badf235f8

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpf502911808bc1b6ee8b26c1badf235f8"
* entry[=].resource = mpf502911808bc1b6ee8b26c1badf235f8
                            
                    
Instance: bundlepackageleaflet-da-f502911808bc1b6ee8b26c1badf235f8
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for slenyto Package Leaflet for language da"
Description: "ePI document Bundle for slenyto Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-f502911808bc1b6ee8b26c1badf235f8"
* entry[0].resource = composition-da-f502911808bc1b6ee8b26c1badf235f8

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpf502911808bc1b6ee8b26c1badf235f8"
* entry[=].resource = mpf502911808bc1b6ee8b26c1badf235f8
                            
                    



Instance: mpf502911808bc1b6ee8b26c1badf235f8
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Slenyto 1 mg prolonged-release tablets"
Description: "Slenyto 1 mg prolonged-release tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/18/1318/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Slenyto 1 mg prolonged-release tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: f502911808bc1b6ee8b26c1badf235f8ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "slenyto"

* status = #current
* mode = #working

* title = "List of all ePIs associated with slenyto"

* subject = Reference(mpf502911808bc1b6ee8b26c1badf235f8)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#slenyto "slenyto"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-f502911808bc1b6ee8b26c1badf235f8) // slenyto en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-f502911808bc1b6ee8b26c1badf235f8) // slenyto da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-f502911808bc1b6ee8b26c1badf235f8
InstanceOf: List

* insert f502911808bc1b6ee8b26c1badf235f8ListRuleset
    